DEA Grants Federal Registration to 900+ Cannabis Dispensaries, Sets November 29 Supply Chain Deadline

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

The DEA has begun issuing federal registrations to more than 900 medical marijuana dispensaries in seven states, the first approvals under the Schedule III framework. Qualifying businesses have until November 29 to verify trading partners and set up compliant supply chains.

• Operators: Verify each trading partner's federal registration or timely application, confirm state licenses and keep records by November 29. Non-compliance risks denial of pending applications or revocation of registrations. Shared medical and recreational infrastructure may force a rethink of relationships.
• Investors: Qualifying Schedule III medical activity is no longer subject to Section 280E deduction limits, and Treasury is encouraged to consider retroactive relief. The DOJ has not named the registered dispensaries, so exposure of any operator is unconfirmed.
• Do now: Audit your supplier, processor, distributor and retail partners today, and collect proof of each one's federal registration or timely application, plus state licenses, before the November 29 deadline.

Short on time? You’re done. Want the numbers?Keep reading ↓

The first federal medical marijuana registrations cover seven states, putting major cannabis operators under a new compliance framework while raising questions about pharmaceutical standards, taxes, and future international trade.

The Drug Enforcement Administration has begun issuing federal registrations to more than 900 medical marijuana dispensaries across seven states, marking the first wave of approvals under the federal government’s new Schedule III framework for qualifying medical cannabis businesses.

The registrations, announced by the Department of Justice on Friday, October 30, cover dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

The announcement also introduces a significant operational deadline. Under separate DEA guidance, qualifying medical cannabis businesses have until November 29 to verify their trading partners and establish supply chains that comply with the new federal framework.

For an industry that has operated largely under state-level regulation despite longstanding federal restrictions, the development introduces a new layer of oversight that could reshape relationships between cultivators, manufacturers, distributors and retailers.

It also raises a broader question: whether federal recognition of medical cannabis businesses will eventually lead to pharmaceutical production standards capable of supporting a more integrated domestic market and, potentially, international trade.

Federal Registration Begins, but Approval Is Not Automatic

The registrations follow the Justice Department’s April 23 order, which moved qualifying medical marijuana into Schedule III while leaving recreational cannabis under Schedule I. Federal approval requires DEA vetting and compliance with security, inventory, and recordkeeping requirements beyond state licensing.

“The regulated distribution of medical marijuana by the applicants that have been granted registration by the Drug Enforcement Administration will help ensure broader access to chronic pain treatment and the safety of the American people,” Blanche said in the October 30 announcement.

The DEA is prioritizing dispensaries that applied during the expedited registration window, while manufacturers and distributors face additional inspections, production controls and quota requirements. Their approval is essential to establishing federally compliant supply chains.

The April 28 final rule goes further, preserving much of the existing state medical cannabis regulatory system under what the Justice Department calls “cooperative federalism.” State licenses remain the foundation of federal registration, which cannot exceed the scope of state authorization and is automatically suspended if the underlying license is suspended, revoked, or expires.

The DEA must accept state-required records and reporting to the maximum extent permitted by federal law, while state rules governing security, packaging, labeling, and disposal can substitute for otherwise applicable federal requirements. State medical certifications also remain valid for dispensing, provided they meet specified federal documentation requirements.

Federal authorities nevertheless retain oversight of registration, diversion prevention, cultivation quotas, inspections, and international treaty compliance. The rule does not establish a universal GACP or GMP requirement for state-licensed medical cannabis production, instead relying substantially on existing state regulatory frameworks while maintaining separate federal controls.

For cultivators, the rule establishes a government-supervised production mechanism under which the DEA formally purchases and resells marijuana crops at nominal prices to satisfy international treaty obligations. It also provides for import and export permits, potentially creating a legal pathway to international medical cannabis trade, although shipments still require separate authorizations.

The tax implications are equally significant. Qualifying Schedule III medical activities are no longer subject to Section 280E’s deduction restrictions, and the rule encourages Treasury to consider retroactive relief for previous tax years. Individual tax liabilities and the treatment of businesses combining medical and recreational operations remain subject to further clarification.

November 29: A New Supply Chain Deadline

The DEA’s accompanying guidance introduces a November 29 deadline for businesses operating under the new medical cannabis framework.

Companies that submitted qualifying applications on time may continue conducting permitted medical marijuana transactions while their registrations remain pending. However, those transactions must involve other timely applicants or federally registered businesses, subject to limited exceptions.

Businesses are expected to verify their trading partners’ eligibility, obtain documentation of federal registration or timely application, confirm applicable state licenses, and retain supporting records.

The agency has also outlined limited accommodations for existing inventory and state-mandated laboratory testing.

Failure to comply could expose businesses to the denial of pending applications or the revocation of existing federal registrations.

For operators, the priority seems to be ensuring that suppliers, processors, distributors, and retail locations form a compliant network.

That could require companies to reassess existing commercial relationships, particularly in markets where medical and recreational cannabis operations share infrastructure.

Which Major Cannabis Operators Have Exposure?

The seven states receiving the initial registrations include several important markets for publicly traded multistate operators.

Florida’s vertically integrated medical cannabis market includes Trulieve (NYSE: TRLV), Verano (OTC: VRNO), Curaleaf (OTC: CURLF), Planet 13 (OTC: PLNH), Cresco Labs (OTC: CRLBF), and AYR-branded operations now under Arboretum ownership. Virginia includes Jushi (OTC: JUSHF), Green Thumb Industries (OTC: GTBIF), Verano and Arboretum, while West Virginia has Trulieve, Verano and Cannabist. Texas operates a more restricted medical program, with Fluent, Texas Original and Goodblend among its established licensees and Trulieve, Verano and Green Thumb involved in its expansion.

Importantly, the DOJ has not publicly identified the individual dispensaries receiving the first federal registrations. Consequently, the presence of these companies in the seven states does not independently establish that any particular operator has received DEA approval.

Why GACP and GMP Could Be the Next Step

Federal registration establishes a legal framework for medical cannabis transactions, but it does not automatically create a uniform pharmaceutical manufacturing system.

That distinction could become increasingly important as regulators determine how to work under Schedule III.

One possible approach would be to align medical cannabis production with internationally recognized Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP).

GACP standards address the cultivation, harvesting, and initial handling of medicinal plants. They establish practices intended to improve consistency, traceability, and control over agricultural inputs and production conditions. Meanwhile, GMP standards apply to manufacturing processes, quality management, documentation, validation, and product consistency.

Together, the two frameworks provide a pathway for connecting agricultural production with pharmaceutical manufacturing requirements.

The European Medicines Agency has established GACP guidance for herbal starting materials used in medicinal products, providing a reference for producers seeking to participate in regulated pharmaceutical markets. Adopting these standards would not eliminate the need for DEA registration, laboratory testing, or other federal requirements. Nor has the DEA announced a general GACP/GMP mandate for the newly registered medical cannabis businesses.

However, incorporating internationally recognized agricultural and manufacturing standards could help address a fundamental challenge facing the U.S. medical cannabis industry: the fragmentation of production and quality requirements across state markets.

Countries including Germany have developed medical cannabis markets in which pharmaceutical quality standards play a central role in determining which products can enter regulated distribution channels.

For U.S. producers, a federal framework built around internationally compatible production standards could eventually position qualifying U.S. cannabis manufacturers to participate in global medical supply chains.

However, the April rule adopts what the Justice Department calls “cooperative federalism,” preserving state licensing, medical certifications, and existing security, recordkeeping, packaging, and disposal standards while retaining federal oversight. It does not establish uniform national production standards or explicitly resolve interstate commerce, leaving questions about how different state compliance systems will operate within a federally regulated supply chain.

The DEA’s new registration framework marks a turning point for medical cannabis operators, but questions remain about federal oversight, state regulatory differences, and the future of interstate and international trade. These challenges will be central to discussions at IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where industry executives, investors, and policymakers will examine the evolving federal cannabis landscape and its implications for businesses nationwide.